A Randomized, Partially-blinded, Placebo-controlled, Ascending Sequential Dose Groups, Single Dose Study of the Safety, Tolerability and Pharmacokinetics of CRV431, Alone and In Combination With Tenofovir Disoproxil Fumarate in Healthy Subjects, With a Pilot Study of Multiple Ascending Sequential Doses in HBV-Infected Subjects on Chronic Tenofovir Disoproxil Fumarate Treatment

Trial Profile

A Randomized, Partially-blinded, Placebo-controlled, Ascending Sequential Dose Groups, Single Dose Study of the Safety, Tolerability and Pharmacokinetics of CRV431, Alone and In Combination With Tenofovir Disoproxil Fumarate in Healthy Subjects, With a Pilot Study of Multiple Ascending Sequential Doses in HBV-Infected Subjects on Chronic Tenofovir Disoproxil Fumarate Treatment

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Aug 2018

At a glance

  • Drugs CRV 431 (Primary) ; Tenofovir disoproxil fumarate (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; First in man
  • Sponsors ContraVir Pharmaceuticals
  • Most Recent Events

    • 23 Jul 2018 Results presented in a ContraVir Pharmaceuticals media release.
    • 23 Jul 2018 According to a ContraVir Pharmaceuticals media release, the company has completed the dosing of the first cohort in Part 1 of this Phase 1/2A trial.
    • 25 Jun 2018 According to a ContraVir Pharmaceuticals media release, the first patient has been dosed in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top